August 2014

Celebrate 2014 Innovation Development Grant Winners

August 1, 2014

Meet our 2014 Innovation Development Grant Winners, with a special focus on Nonsurgical Treatment for Type 2 Diabetes. Nonsurgical Treatment for Type 2 Diabetes Ali Tavakkoli, MD, BWH, Gastrointestinal and General Surgery Type-2 diabetes mellitus (T2DM) affects more than 11% of the US adult population with 35% of US adults having pre-diabetic symptoms- incidence continues…

IT Enhances Care, Research, and Operations

August 1, 2014

In keeping with Partners HealthCare rich history of discovery, clinicians and technologists are setting the pace for innovation in health care IT. Technological feats ranging from virtual visits to personalized medicine are redefining modern health care and inspiring a slew of questions about the limits—and seemingly endless possibilities—of information technology. The rapidly expanding digital health…

Targeting Nanotechnology: BIND Therapeutics

August 1, 2014

A look into the targeted nanoparticle therapies known as Accurins—developed by BIND Therapeutics, the brainchild of Partners HealthCare innovator Omid Farokhzad, MD, and MIT legend Robert Langer, ScD. Cancer cells may give traditional chemotherapies short shrift, but the targeted nanoparticle therapies known as Accurins—developed by BIND Therapeutics, the brainchild of Partners HealthCare innovator Omid Farokhzad,…

Two Landmark Drugs: Serendipity Drives Science

August 1, 2014

Earlier this year the FDA approved two new breakthrough therapies for hemophilia patients — Alprolix and Eloctate. Two landmark therapies for hemophilia won FDA approval earlier this year, capping off one of Partners HealthCare's top innovator's 22-year journey of a failed laboratory experiment to dazzling success. Earlier this year the FDA approved two new breakthrough…